Evidence map›Paper›PMID 41844711›Full record

ArticleScientific reports2026

ASCC3 promotes chemosensitivity in colorectal cancer cells.

Anqianyi Tu, Rebecca D C Martyn, Shixin Cui, Nicole L Batenburg, Russta Fayyazi, Fiorella Di Pastena, Line Berthiaume, Kanwaldeep Singh, Ranim Saleem, Graham R Scott and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anqianyi TuDepartment of Biology, McMaster University, Hamilton, Ontario, Canada.
Rebecca D C MartynDepartment of Biology, McMaster University, Hamilton, Ontario, Canada.
Shixin CuiDepartment of Biology, McMaster University, Hamilton, Ontario, Canada.
Nicole L BatenburgDepartment of Biology, McMaster University, Hamilton, Ontario, Canada.
Russta FayyaziCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Fiorella Di PastenaCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Line BerthiaumeEndocrinology and Nephrology Research Division, Centre de recherche du CHU de Québec - Université Laval, Québec City, Québec, Canada.
Kanwaldeep SinghDepartment of Oncology, McMaster University, Hamilton, Ontario, Canada.
Ranim SaleemDepartment of Biology, McMaster University, Hamilton, Ontario, Canada.
Graham R ScottDepartment of Biology, McMaster University, Hamilton, Ontario, Canada.
Tobias BergDepartment of Oncology, McMaster University, Hamilton, Ontario, Canada.
Étienne Audet-WalshEndocrinology and Nephrology Research Division, Centre de recherche du CHU de Québec - Université Laval, Québec City, Québec, Canada.
Gregory R SteinbergCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Xu-Dong ZhuDepartment of Biology, McMaster University, Hamilton, Ontario, Canada. zhuxu@mcmaster.ca.

Funding

Cancer Research Society 1454461
6 · The paper itself

Abstract

The activating signal co-integrator 1 complex subunit 3 (ASCC3), a multifunctional protein, has been implicated as a prognostic marker in several types of cancer. However, mechanisms underlying its prognostic value are not fully understood. Here, we report that ASCC3 promotes sensitivity to chemotherapeutic drugs that induce replication stress, such as 5-fluorouracil, cisplatin, and hydroxyurea, in colorectal cancer (CRC) cells, likely in a cancer type dependent manner. Increased chemoresistance resulting from ASCC3 loss is not due to reduced genomic instability as evidenced by enhanced accumulation of DNA damage and micronuclei following exposure to these drugs. RNA-seq analysis reveals that ASCC3 stimulates the expression of gene sets associated with mTORC1 signaling, glycolysis, and protein folding pathways in CRC cells. While promoting the serine biosynthesis pathway, we demonstrate, through extracellular flux assays and stable isotopes tracer analysis, that ASCC3 reprograms energy metabolism, favoring glycolysis over oxidative phosphorylation. Furthermore, we find that ASCC3 is required for PERK production upon ER stress. Impaired PERK production is associated with reduced levels of CHOP and caspase 3 following treatment with 5-fluorouracil, indicating that ASCC3 promotes PERK production to enhance cell death upon chemotherapy. Collectively, our work reveals an unexpected role of ASCC3 in connecting replication stress to both metabolic reprogramming and PERK-mediated signaling in CRC cells.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsDrug Resistance, NeoplasmCell Line, TumorCisplatineIF-2 KinaseEndoplasmic Reticulum StressFluorouracilGene Expression Regulation, NeoplasticGlycolysisHumansHydroxyureaMechanistic Target of Rapamycin Complex 1Metabolic ReprogrammingSignal TransductionAntineoplastic AgentsCisplatineIF-2 KinaseFluorouracilHydroxyureaMechanistic Target of Rapamycin Complex 1ASCC3ChemoresistanceColorectal cancerPERK productionReprogramming of energy metabolism

Identifiers

PMID41844711
PMCPMC13128862

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.